Combined immunotherapy with nivolumab and ipilimumab with and without sequential or concomitant stereotactic radiotherapy in patients with melanoma brain metastasis: An international retrospective study
Mario Mandalà(University of Perugia), Paolo A. Ascierto(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"), Marco Tucci(Prostate Cancer UK), Ana Arance(Hospital Clínic de Barcelona), Joanna Placzke(The Maria Sklodowska-Curie National Research Institute of Oncology), Anna Maria Di Giacomo(University of Siena), Maria Chiara Sergi(Azienda Universitaria Ospedaliera Consorziale - Policlinico Bari), Angela Hong(The University of Sydney), Teresa Amaral(University of Tübingen), Michele Guida(Istituto Tumori Bari), Francesco Spagnolo(Martin University), Eva Muñoz‐Couselo(Vall d'Hebron Hospital Universitari), Ernesto Rossi(Agostino Gemelli University Polyclinic), Inês Pires da Silva(The University of Sydney), Pietro Quaglino(Department of Medical Sciences), Paul Lorigan(Manchester Academic Health Science Centre), Roberta Depenni(University of Modena and Reggio Emilia), Paola Queirolo, Iris Dirven(Universitair Ziekenhuis Brussel), Bart Neyns(Universitair Ziekenhuis Brussel), Naima Benannoune(Institut Gustave Roussy), Diana Giannarelli(Agostino Gemelli University Polyclinic), M. Nyhuus Bendix Rasch(University of Tübingen), Caroline Robert(Institut Gustave Roussy), Patricio Serra(University of Manchester), Alexander M Menzies(The University of Sydney), Maria Grazia Vitale(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"), Georgina V Long(The University of Sydney), Michele Del Vecchio(Fondazione IRCCS Istituto Nazionale dei Tumori), Piotr Rutkowski(The Maria Sklodowska-Curie National Research Institute of Oncology), Alice Indini(Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico)
Cited by 7
Related Papers
Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
|New England Journal of Medicine|2011|7.7k
Pembrolizumab versus Ipilimumab in Advanced Melanoma
|New England Journal of Medicine|2015|5.9k
Nivolumab in Previously Untreated Melanoma without <i>BRAF</i> Mutation
|New England Journal of Medicine|2014|5.3k
Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma
|New England Journal of Medicine|2013|3.4k
Improved Overall Survival in Melanoma with Combined Dabrafenib and Trametinib
|New England Journal of Medicine|2014|2.7k